← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Progenra, Inc.
Malvern, PA
$23,966,396
Total funding
53
Grants
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,966,396 · 53
By mechanism
R44$12,335,566 · 10
R43$10,685,993 · 41
R01$605,743 · 1
R41$339,094 · 1
Investigators at Progenra, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Ubiquitin pathway inhibitors for treatment of asthma$757,044
R44 · FY2017 · AI
Chemical Optimization of a novel class of USP7 inhibitor for cancer treatment$748,944
R44 · FY2016 · CA
Chemical Optimization of a novel class of USP7 inhibitor for cancer treatment$748,944
R44 · FY2017 · CA
Small molecule Parkin activators to treat Alzheimer's Disease$741,032
R44 · FY2017 · AG
Ubiquitin E3 ligase detection by fluorescence resonance transfer$723,331
R44 · FY2014 · GM
Screen for MURF-1 inhibitors to treat myopathy$694,309
R44 · FY2009 · AG
Novel molecular therapeutics for cystic fibrosis$668,380
R44 · FY2014 · HL
Novel molecular therapeutics for cystic fibrosis$667,073
R44 · FY2015 · HL
Molecular screens for pVHL-associated isopeptidase VDU1$650,617
R44 · FY2007 · CA
Small molecule Parkin activators to treat Alzheimer's Disease$643,048
R44 · FY2018 · AG
Ubiquitin pathway inhibitors for treatment of asthma$636,155
R44 · FY2018 · AI
Selective inhibitors of ubiquitin E3 ligase to treat high cholesterol$611,663
R44 · FY2014 · ES
Selective inhibitors of ubiquitin E3 ligase to treat high cholesterol$611,663
R44 · FY2015 · ES
Ubiquitin E3 ligase detection by fluorescence resonance transfer$611,190
R44 · FY2015 · GM
Molecular screen for isopeptidase inhibitors to treat pulmonary disease$517,089
R44 · FY2010 · HL
Osteoporosis Screen for Praja1 E3 Ligase Inhibitors$497,620
R44 · FY2007 · AG
Molecular screen for isopeptidase inhibitors to treat pulmonary disease$467,549
R44 · FY2011 · HL
Osteoporosis Screen for Praja1 E3 Ligase Inhibitors$417,549
R44 · FY2008 · AG
Screen for MURF-1 inhibitors to treat myopathy$374,158
R44 · FY2010 · AG
Molecular Screens for Deubiquitinase Function$363,348
R43 · FY2005 · DK